Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure
INTERPACE BIOSCIENCES, INC. (IDXG) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results"
05/12/2023 8-K Quarterly results
Docs: "Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results"
03/27/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
Docs: "INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue, net $ 10,853 $ 9,646 $ 41,314 $ 32,398 Cost of revenue 6,404 6,517 23,369 21,673 Gross Profit 4,449 3,129 17,945 10,725 Sales and marketing 2,482 2,478 10,067 9,254 Research and development 407 673 1,882 2,795 General and administrative 4,030 5,508 13,669 18,192 Transition expenses 111 1,780 2,585 2,578 Loss on DiamiR transaction 248 - 13 - Acquisition amortization expense 728 1,115 4,064 4,461 Change in fair value of contingent consideration Total operating expenses 7,725 11,065 31,942 36,791 Operating loss Interest accretion expense Related party interest - - Other income, net 467 Loss from continuing operations before ta..."
11/10/2021 8-K Quarterly results
Docs: "INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue, net $ 9,472 $ 8,248 $ 30,461 $ 22,752 Cost of revenue 5,848 5,194 16,965 15,156 Gross Profit 3,624 3,054 13,496 7,596 Sales and marketing 2,456 2,699 7,585 6,776 Research and development 416 763 1,475 2,123 General and administrative 3,278 3,795 9,582 12,683 Transition expenses 363 687 2,474 798 Gain on DiamiR transaction - - - Acquisition amortization expense 1,112 1,115 3,336 3,346 Total operating expenses 7,625 9,059 24,217 25,726 Operating loss Interest accretion expense Related party interest - - Other income , net 45 473 Loss from continuing operations before tax provision for income taxes 14 43 Loss from cont..."
05/11/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
01/20/2021 8-K Quarterly results
Docs: "Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan"
10/20/2020 8-K Quarterly results
Docs: "Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results"
06/25/2020 8-K Quarterly results
04/22/2020 8-K Quarterly results
Docs: "Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results"
08/13/2019 8-K Quarterly results
Docs: "Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update"
05/13/2019 8-K Quarterly results
Docs: "Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update"
02/28/2019 8-K Quarterly results
Docs: "Interpace Diagnostics Announces Preliminary 2018 Revenues"
11/13/2018 8-K Quarterly results
Docs: "Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments"
08/09/2018 8-K Quarterly results
Docs: "Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Recent Accomplishments"
11/13/2017 8-K Quarterly results
Docs: "Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments"
08/10/2017 8-K Quarterly results
Docs: "Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent Accomplishments"
05/15/2017 8-K Form 8-K - Current report
11/18/2016 8-K Quarterly results
Docs: "Interpace Diagnostics Group, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Revenue, net $ 3,316 $ 2,506 $ 9,963 $ 6,876 Cost of revenue 1,846 1,799 4,866 5,224 Gross Profit 1,470 707 5,097 1,652 Sales and marketing 1,282 2,876 4,186 8,387 Research and development 659 1,000 1,339 1,646 General and administrative 2,858 2,498 7,655 8,909 Acquisition related amortization expense 970 986 2,909 2,825 Asset impairment 3,363 - 3,363 - Change in fair value of contingent consideration - - Total operating expenses 7,958 7,360 18,278 21,767 Operating loss Interest expense Other income , net 4 14 Loss from continuing operations before tax Income tax expense 173 Loss from continuing operations income fro..."
05/13/2016 8-K Form 8-K - Current report
11/03/2014 8-K Quarterly results
Docs: "PDI Reports 2014 Third Quarter Financial Results; Acquires RedPath Integrated Pathology Management Will Host Conference Call Today November 3 at 8:00 am ET"
08/19/2014 8-K/A Quarterly results
Docs: "PDI Reports 2014 Second Quarter Financial Results Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET"
08/13/2014 8-K Quarterly results
Docs: "PDI Reports 2014 Second Quarter Financial Results Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET"
05/07/2014 8-K Quarterly results
Docs: "PDI Reports 2014 First Quarter Financial Results Management Will Host Conference Call Tomorrow May 8 at 8:30 am ET"
11/12/2013 8-K Form 8-K - Current report
08/05/2013 8-K Form 8-K - Current report
05/13/2013 8-K Quarterly results
Docs: "PDI Reports 2013 First Quarter Financial Results Management to Host Conference Call Tomorrow, May 14, 2013 at 8:30AM ET"
11/05/2012 8-K Form 8-K - Current report
08/13/2012 8-K Form 8-K - Current report
05/14/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy